AR123935A1 - COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g - Google Patents
COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d gInfo
- Publication number
- AR123935A1 AR123935A1 ARP210102983A ARP210102983A AR123935A1 AR 123935 A1 AR123935 A1 AR 123935A1 AR P210102983 A ARP210102983 A AR P210102983A AR P210102983 A ARP210102983 A AR P210102983A AR 123935 A1 AR123935 A1 AR 123935A1
- Authority
- AR
- Argentina
- Prior art keywords
- cell
- antibody
- target
- trgdc
- trdv2
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000036039 immunity Effects 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 10
- 210000004027 cell Anatomy 0.000 abstract 5
- 108091008874 T cell receptors Proteins 0.000 abstract 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 4
- 102100025137 Early activation antigen CD69 Human genes 0.000 abstract 3
- 102000001398 Granzyme Human genes 0.000 abstract 3
- 108060005986 Granzyme Proteins 0.000 abstract 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 abstract 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 abstract 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 abstract 3
- 101000649129 Homo sapiens T cell receptor delta variable 2 Proteins 0.000 abstract 3
- 101000680681 Homo sapiens T cell receptor gamma variable 9 Proteins 0.000 abstract 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 abstract 3
- 102100027948 T cell receptor delta variable 2 Human genes 0.000 abstract 3
- 102100022393 T cell receptor gamma variable 9 Human genes 0.000 abstract 3
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 239000013598 vector Substances 0.000 abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
En la presente descripción, en ciertos aspectos, se proporcionan anticuerpos que se unen al receptor de células T (TCR) Vg9 (TRGV9), TCR Vd2 (TRDV2), o la región constante g / d del TCR (TRGDC), así como células recombinantes que contienen los vectores y composiciones que comprenden los anticuerpos. También se proporcionan métodos para preparar y usar los anticuerpos. Reivindicación 24: Una secuencia de ácido nucleico que codifica el anticuerpo de una cualquiera de las reivindicaciones 1 a 23. Reivindicación 25: Un vector que comprende la secuencia de ácido nucleico de la reivindicación 24. Reivindicación 26: Una célula huésped que comprende el vector de la reivindicación 25. Reivindicación 29: Una composición farmacéutica que comprende el anticuerpo de una cualquiera de las reivindicaciones 1 a 23, y un portador farmacéuticamente aceptable. Reivindicación 30: Un método para producir la composición farmacéutica de la reivindicación 28, que comprende combinar el anticuerpo con un portador farmacéuticamente aceptable para obtener la composición farmacéutica. Reivindicación 31: Un método para dirigir una célula T gd a una célula diana, el método comprende poner en contacto la célula T gd con el anticuerpo multiespecífico de la reivindicación 23, en donde la célula diana expresa la segunda diana, y en donde el contacto hace que la célula T gd se dirija a la célula diana. Reivindicación 37: Un método para activar una célula T, en donde: (a) la célula T expresa TRGV9, y el método comprende poner en contacto la célula T con el anticuerpo de una cualquiera de las reivindicaciones 1, 4 a 12, ó 21 a 23; en donde opcionalmente el contacto resulta en un aumento en la expresión de CD69, CD25, y/o granzima B, en comparación con una célula T de control que expresa TRGV9; (b) la célula T expresa TRDV2, y el método comprende poner en contacto la célula T con el anticuerpo de una cualquiera de las reivindicaciones 2, 4 a 8, 13 a 16, ó 21 a 23; en donde opcionalmente el contacto resulta en un aumento en la expresión de CD69, CD25, y/o granzima B, en comparación con una célula T de control que expresa TRDV2; o (c) la célula T expresa TRGDC, y el método comprende poner en contacto la célula T con el anticuerpo de una cualquiera de las reivindicaciones 3 a 8, ó 17 a 23; en donde opcionalmente el contacto resulta en un aumento en la expresión de CD69, CD25, y/o granzima B, en comparación con una célula T de control que expresa TRGDC.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063106703P | 2020-10-28 | 2020-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123935A1 true AR123935A1 (es) | 2023-01-25 |
Family
ID=81256812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102983A AR123935A1 (es) | 2020-10-28 | 2021-10-27 | COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12076413B2 (es) |
| EP (1) | EP4237003A4 (es) |
| JP (1) | JP2023548109A (es) |
| KR (1) | KR20230093503A (es) |
| CN (1) | CN116390950A (es) |
| AR (1) | AR123935A1 (es) |
| AU (1) | AU2021372463A1 (es) |
| CA (1) | CA3199767A1 (es) |
| TW (1) | TW202233674A (es) |
| UY (1) | UY39488A (es) |
| WO (1) | WO2022093888A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230132604A (ko) | 2015-01-27 | 2023-09-15 | 라바 테라퓨틱스 엔.브이. | Cd1d를 표적화하는 단일 도메인 항체 |
| US12077586B2 (en) | 2018-09-19 | 2024-09-03 | LAVA Therapeutics N.V. | Bispecific antibodies for use in the treatment of hematological malignancies |
| BR112021022089A2 (pt) | 2019-05-08 | 2022-02-08 | Janssen Biotech Inc | Materiais e métodos para modulação da imunidade mediada por células t |
| JP2023532807A (ja) | 2020-07-08 | 2023-07-31 | ラヴァ・セラピューティクス・エヌ・ヴイ | Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体 |
| WO2025229538A1 (en) | 2024-05-01 | 2025-11-06 | Janssen Biotech, Inc. | Materials, methods, and systems for cellular expansion of gamma delta t-cells |
| WO2026013159A1 (en) | 2024-07-10 | 2026-01-15 | Cytospire Therapeutics Limited | Antibodies binding to constant domains of gamma delta t-cell receptors |
| WO2026013158A1 (en) | 2024-07-10 | 2026-01-15 | Cytospire Therapeutics Limited | Antibodies binding to constant domains of gamma delta t-cell receptors |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1449539A2 (en) | 1996-10-31 | 2004-08-25 | Mochida Pharmaceutical Co., Ltd. | Prophylactic or therapeutic use of a Fas antagonist to inhibit Fas-mediated apoptosis |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2467738A1 (en) | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Antibodies against carboxic anhydrase ix (ca ix) tumor antigen |
| JP2008511337A (ja) | 2004-09-02 | 2008-04-17 | ジェネンテック・インコーポレーテッド | ヘテロ多量体分子 |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| EP2035456A1 (en) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production of bispecific antibodies |
| CA2694488A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| AU2009204501B2 (en) | 2008-01-07 | 2015-02-12 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
| WO2010045340A1 (en) | 2008-10-14 | 2010-04-22 | Centocor Ortho Biotech Inc. | Methods of humanizing and affinity-maturing antibodies |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| CA2772929A1 (en) | 2009-09-03 | 2011-03-11 | Genentech, Inc. | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
| CN110066339A (zh) | 2010-04-20 | 2019-07-30 | 根马布股份公司 | 含异二聚体抗体fc的蛋白及其制备方法 |
| RU2595385C2 (ru) | 2010-08-05 | 2016-08-27 | Анаптисбайо, Инк. | Антитела, направленные против il-17 |
| HUE047228T2 (hu) | 2010-11-05 | 2020-04-28 | Zymeworks Inc | Stabil heterodimer antitest-kialakítás az FC doménben mutációval |
| EP3321286B1 (en) | 2011-08-23 | 2021-01-06 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| JP6326371B2 (ja) | 2011-11-04 | 2018-05-16 | ザイムワークス，インコーポレイテッド | Ｆｃドメインにおける変異を有する安定なヘテロ二量体抗体デザイン |
| EA201400709A1 (ru) | 2011-12-19 | 2016-08-31 | Синиммун Гмбх | Молекула биспецифического антитела |
| KR102359264B1 (ko) * | 2014-04-10 | 2022-02-04 | 라바 테라퓨틱스 비.브이. | 인간 Vγ9Vδ2 T 세포에 결합하는 면역글로불린 |
| US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| CN107849144B (zh) * | 2015-05-29 | 2021-09-17 | 艾吉纳斯公司 | 抗-ctla-4抗体及其使用方法 |
| MY197345A (en) | 2015-11-25 | 2023-06-14 | Visterra Inc | Antibody molecules to april and uses thereof |
| US11117963B2 (en) | 2016-12-26 | 2021-09-14 | Kyowa Hakko Kirin Co., Ltd. | Antibody which binds to myelin oligodendrocyte glycoprotein |
| EP3743081A4 (en) | 2018-01-23 | 2021-12-01 | New York University | SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR |
| BR112021022089A2 (pt) | 2019-05-08 | 2022-02-08 | Janssen Biotech Inc | Materiais e métodos para modulação da imunidade mediada por células t |
| IL295897A (en) | 2020-02-27 | 2022-10-01 | Janssen Biotech Inc | Materials and methods for modulating an immune response |
| US20210284731A1 (en) | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Methods and materials for modulating an immune response |
| KR20220154190A (ko) | 2020-03-13 | 2022-11-21 | 얀센 바이오테크 인코포레이티드 | 델타 사슬 매개 면역을 조절하기 위한 물질 및 방법 |
-
2021
- 2021-10-27 KR KR1020237017991A patent/KR20230093503A/ko not_active Withdrawn
- 2021-10-27 AR ARP210102983A patent/AR123935A1/es unknown
- 2021-10-27 UY UY0001039488A patent/UY39488A/es unknown
- 2021-10-27 JP JP2023525958A patent/JP2023548109A/ja active Pending
- 2021-10-27 EP EP21887391.7A patent/EP4237003A4/en active Pending
- 2021-10-27 US US17/512,195 patent/US12076413B2/en active Active
- 2021-10-27 CA CA3199767A patent/CA3199767A1/en active Pending
- 2021-10-27 AU AU2021372463A patent/AU2021372463A1/en not_active Abandoned
- 2021-10-27 TW TW110139845A patent/TW202233674A/zh unknown
- 2021-10-27 CN CN202180074296.XA patent/CN116390950A/zh active Pending
- 2021-10-27 WO PCT/US2021/056744 patent/WO2022093888A1/en not_active Ceased
-
2024
- 2024-08-22 US US18/812,337 patent/US20240424130A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12076413B2 (en) | 2024-09-03 |
| AU2021372463A9 (en) | 2025-03-20 |
| CA3199767A1 (en) | 2022-05-05 |
| EP4237003A4 (en) | 2025-07-09 |
| UY39488A (es) | 2022-04-29 |
| JP2023548109A (ja) | 2023-11-15 |
| TW202233674A (zh) | 2022-09-01 |
| US20240424130A1 (en) | 2024-12-26 |
| AU2021372463A1 (en) | 2023-06-22 |
| EP4237003A1 (en) | 2023-09-06 |
| US20220125947A1 (en) | 2022-04-28 |
| KR20230093503A (ko) | 2023-06-27 |
| WO2022093888A1 (en) | 2022-05-05 |
| CN116390950A (zh) | 2023-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123935A1 (es) | COMPOSICIONES Y MÉTODOS PARA MODULAR LA INMUNIDAD MEDIADA POR LA CADENA d g | |
| AR069776A1 (es) | Anticuerpos bivalentes biespecificos | |
| AR126987A2 (es) | Inmunoconjugados | |
| PE20211498A1 (es) | Anticuerpos dirigidos contra il-11 | |
| AR132144A2 (es) | ANTICUERPOS ANTI-FcRn | |
| AR118118A2 (es) | Anticuerpos bivalentes biespecíficos | |
| CL2024002235A1 (es) | Anticuerpo anti-cd73 humano; método de producción; composición farmacéutica; y su uso. | |
| PE20211500A1 (es) | Anticuerpos dirigidos contra il-11ra | |
| PE20230160A1 (es) | Anticuerpos especificos para cd47, pd-l1 y sus usos | |
| BR112019000512A2 (pt) | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit | |
| BRPI0812091A2 (pt) | Método para fabricar uma proteína policlonal recombinante | |
| BR112015019603A2 (pt) | Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna | |
| AR074124A1 (es) | Composiciones y metodos para inhibir la expresion de genes del factor vii | |
| BRPI0619579B8 (pt) | Métodos para aumentar a expectativa de vida replicativa e/ou estabilidade de uma célula produtora de anticorpo, para expressar um gene de uma célula b codificando a cadeia pesada de ig e/ou cadeia leve de ig, para produzir linhagem de células b, para obter anticorpos, e, método ex vivo para produzir anticorpos capazes de especificamente ligar um antígeno de interesse | |
| AR107444A1 (es) | Composición farmacéutica que comprende constructos de anticuerpo biespecíficos | |
| CL2023002099A1 (es) | Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos | |
| AR085404A1 (es) | Proteinas de union a antigeno | |
| AR063840A1 (es) | Anticuerpos humanos monoclonales para btla y metodos de uso | |
| BR112012026766A2 (pt) | métodos in vitro para gerar uma proteína heterodimérica, para a seleção de um anticorpo biespecífico e para inibir o crescimento, vetor de expressão, célula hospedeira, proteína heterodimérica, composição farmacêutica. | |
| BR112016007547A2 (pt) | ?vetor de expressão bicistrônico para expressão de anticorpos e método para a produção de anticorpos usando o mesmo? | |
| AR109451A1 (es) | Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión | |
| UY39617A (es) | Proteínas de unión a psma y usos de estas | |
| MX2021015698A (es) | Integración dirigida de configuraciones aleatorias de ácidos nucleicos. | |
| CO2025005381A2 (es) | Construcciones t car que comprenden un nuevo aglutinante cd19 combinado con il18 y métodos para usar el mismo | |
| CO2025016094A2 (es) | Anticuerpo biespecífico dirigido al receptor acoplado a proteína g |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |